ABOUT US

A global leader in innovative genomic
technology and diagnostic tests.


What’s new at Agendia?

Get the latest updates on our company and products, as well as new developments in genomic science.

News

In the News

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

Two women reading about genomic breast cancer results

Latest Data

Agendia Presents New Data Demonstrating MammaPrintโ€™s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients [โ€ฆ]

I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go โ€œbeyond the mammogramโ€ in a portrait series illustrating people touched by breast cancer.

News

Media Releases

New Research to be Presented at SABCS 2018 Reinforces MammaPrint and BluePrint Testing to Guide Breast Cancer Treatment Management Decisions

December 5th, 2018|

PRESS RELEASE Agendia Announces New Research Reinforcing MammaPrintยฎ and BluePrintยฎ Testing to Guide Breast Cancer Treatment Management Decisions Across Different Patient Populations and Ages at the 2018 San Antonio Breast Cancer Symposium IRVINE, CA, AMSTERDAM, Read More

Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrintยฎ and BluePrintยฎ to Predict Treatment Response in Breast Cancer Patients

November 14th, 2018|

ย PRESS RELEASE Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrintยฎ and BluePrintยฎ to Predict Treatment Response in Breast Cancer Patients New data from the trial shows that a Read More

Agendia Announces Level 1 Inclusion of MammaPrintยฎ Breast Cancer Test in Updated National Comprehensive Cancer Networkยฎ (NCCN) Guidelines

October 9th, 2018|

PRESS RELEASE Agendia Announces Level 1 Inclusion of MammaPrintยฎ Breast Cancer Test in Updated National Comprehensive Cancer Networkยฎ (NCCN) Guidelines The NCCN recommends Agendiaโ€™s MammaPrintยฎ breast cancer test with the highest level of evidence for Read More